PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs CP 101 Crestovo (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRISM-EXT
- Sponsors Finch Research & Development
- 16 Aug 2019 Planned End Date changed from 1 May 2020 to 1 Aug 2020.
- 16 Aug 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Feb 2020.
- 02 Aug 2018 Status changed from not yet recruiting to recruiting.